neurotrophic keratitis

EMA committee recommends cenegermin for neurotrophic keratitisA committee of the European Medicines Agency has recommended approval of cenegermin (Oxervate, Dompé) eye drops for neurotrophic keratitis.
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval
Neurotrophic keratitis treatment gains orphan drug designationThe FDA has designated Dompé’s rhNGF (recombinant human nerve growth factor) as an orphan drug for the treatment of neurotrophic keratitis.
Study finds possible new treatment of corneal ulcers in neurotrophic keratitis patientsItalian biopharmaceutical company Dompé is researching recombinant human nerve growth factor (rhNGF) for the treatment of corneal ulcers in patients affected by neurotrophic keratitis.